Stephen Feider sold $108k of BBNX
Chief Financial Officer at Beta Bionics, Inc.. 4,982 shares at an average of $21.69, traded Oct 3, 2025, filed Oct 7, 2025.
Score components
- +22RoleCFO
- +10Trade size$108k at market
- +5Share of holdings soldSold 10% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +13.0%, 3m +41.8%, 6m -56.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002048588-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 3, 2025 | MOption exercise Common Stock10b5-1 | +4,982 | $5.10 | $25k | 49,023 | Oct 7, 2025 |
| Oct 3, 2025 | SOpen-market sale Common Stock10b5-1 | -3,828 | $21.52 | $82k | 45,195 | Oct 7, 2025 |
| Oct 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1,154 | $22.28 | $26k | 44,041 | Oct 7, 2025 |
| Oct 3, 2025 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,982 | $0.00 | $0 | 69,695 | Oct 7, 2025 |
Related signals
Other insiders at Beta Bionics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $7,015 370 shares | -1% | |
| 26Weak | Beta Bionics, Inc. | Christy Jones director | $148k 6,430 shares | -25% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $665k 35,994 shares | -29% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $620k 30,779 shares | -35% | |
| 17Weak | Beta Bionics, Inc. | Mike Mensinger Chief Product Officer | $58k 2,650 shares | -1% | |
| 10Weak | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $12k 775 shares | -1% | |
| 41Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $681k 36,870 shares | -30% | |
| 30Weak | Beta Bionics, Inc. | Sean Saint President & CEO | $113k 5,641 shares | -1% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $102k 5,327 shares | -4% | |
| 39Weak | Beta Bionics, Inc. | Mike Mensinger Chief Product Officer | $84k 4,375 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.